AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS 11.11.2024 18:08 Fiercebiotech.com AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS ntaylor Mon, 11/11/2024 - 10:08
